This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human Thrombospondin-2 Protein, His Tag
catalog :
TH2-H52H5
quantity :
1 mg, 100 ug
price :
2310 USD, 350 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
TH2-H52H5
product name :
Human Thrombospondin-2 Protein, His Tag
quantity :
1 mg, 100 ug
price :
2310 USD, 350 USD
quantity & price :
$350/100ug,$2310/1mg (200ug × 5)
target :
Thrombospondin-2
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human Thrombospondin-2, His Tag (TH2-H52H5) is expressed from human 293 cells (HEK293). It contains AA Gly 19 - Ile 1172 (Accession # P35442-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>90% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human Thrombospondin-2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Thrombospondin-2 is also known as THBS2, TSP2, TSP-2. Thrombospondin-2 (TSP2) is an anti-angiogenic matricellular protein that inhibits tumor growth and angiogenesis. Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. Ligand for CD36 mediating antiangiogenic properties. 2 SNPs in the intron region of THBS2 gene (rs6422747 and rs6422748) were associated with susceptibility of IDD. However, they were not related with severity of IDD, including the total number of degenerative disc and level of IDD. Thrombospondin 2, an important regulator of synaptogenesis in central nervous system development, was distributed in retinal macroglia cells, and its receptor α2δ-1 was in retinal neurons. activated macroglia cells may participate in alterations of presynaptic proteins of retinal neurons following elevated hydrostatic pressure, and macroglia-derived thrombospondin 2 may modulate these changes via binding to its neuronal receptor α2δ-1.
References :
(1) Yuan B, et al. 2018, Medicine (Baltimore), 97(2):e9586.
(2) Roudnicky F, et al. 2018, Oncogene., 37(19):2573-2585.
(3) Wang S, et al. 2017, PLoS One, 12(9):e0185388.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments